Endogenous ouabain in cardiovascular function and disease

Journal of Hypertension

Volumn 27, Issue 1, 2009, Pages 9-18

  Manunta, Paolo ^a,d   Ferrandi, Mara ^b   Bianchi, Giuseppe ^a   Hamlyn, John M ^c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Prassis Sigma Tau Research Institute   (Italy)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Digitalis like factor; Hypertension; Na pump inhibitor; Natriuresis; Renal; Sodium

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); OUABAIN; CARDENOLIDE; DIGOXIN LIKE FACTORS; DIGOXIN-LIKE FACTORS; SAPONIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ADRENAL GLAND; BIOSYNTHESIS; BODY FLUID; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CONGESTIVE HEART FAILURE; DIETARY INTAKE; DISEASE ASSOCIATION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SALT INTAKE; SODIUM CALCIUM EXCHANGE; ANIMAL; BLOOD; CHEMISTRY; DIET; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RADIOIMMUNOASSAY; SECRETION;

ADRENAL CORTEX; ANIMALS; BODY FLUIDS; CARDENOLIDES; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIET; HUMANS; OUABAIN; RADIOIMMUNOASSAY; SAPONINS;

EID: 58849148597     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831cf2c6     Document Type: Review

References (112)

1. Szent-Gyorgyi A. Chemical physiology of contraction in body and heart muscle. New York: Academic Press; 1953. pp. 86-91.
2. DeWardener HE,Mills IH,ClaphamWF,HayterCJ. Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci 1961; 21:249-258.
3. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am J Physiol Cell Physiol 1977; 232:C167-C173.
4. Dahl LK, Knudsen KD, Heine M, Leitl G. Effects of chronic excess salt ingestion. Genetic in?uence on the development of salt hypertension in parabiotic rats. Evidence for a circulating factor. J Exp Med 1967; 126:687-699.
5. deWardener HE,MacGregorGA. Sodiumand blood pressure. CurrOpin Cardiol 2002; 17:360-367.
6. Hamlyn JM, Ringel R, Schaeffer J, Levinson PD, Hamilton BP, Kowarski AA, Blaustein MP. A circulating inhibitor of (Na-K)ATPase associated with essential hypertension. Nature 1982; 300:650-652.
7. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Mandel F, Mathews WR, Ludens JH. Identi?cation and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991; 88:6259-6263.
8. Nicholls MG, Lewis LK, Yandle TG, Lord G, McKinnon W, Hilton PJ. Ouabain, a circulating hormone secreted by the adrenals, is pivotal in cardiovascular disease: fact or fantasy? J Hypertens 2008; 26:000-000.
9. Lorenz JN, Loreaux EL, Dostanic-Larson I, Lasko V, Schnetzer JR, Paul RJ, Lingrel JB. ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na-K-ATPase subunit. Am J Physiol Heart Circ Physiol 2008; 295:H273-H280.
10. Dostanic-Larson I, Van Huysse JW, Lorenz JN, Lingrel JB. The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci USA 2005; 102:15845-15850.
11. Dostanic-Larson I, Lorenz JN, Van Huysse JW, Neumann JC, Moseley AE, Lingrel JB. Physiological role of the alpha1- and alpha2-isoforms of the Na-K-ATPase and biological signi?cance of their cardiac glycoside binding site. Am J Physiol Regul Integr Comp Physiol 2006; 290:R524-R528.
12. Zhang J, Lee MY, Cavalli M, Chen L, Berra-Romani R, Balke CW, et al. Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice. J Physiol 2005; 569 (Pt 1):243-256.
13. Iwamoto T, Kita S, Zhang J, Blaustein MP, Arai Y, Yoshida S, et al. Salt-sensitive hypertension is triggered by Ca2 entry via Na/Ca2 exchanger type-1 in vascular smooth muscle. Nat Med 2004; 10:1193-1199.
14. Liang M, Tian J, Liu L, Pierre S, Liu J, Shapiro J, Xie ZJ. Identi?cation of a pool of nonpumping Na/K-ATPase. J Biol Chem 2007; 282:10585-10593.
15. Liang M, Cai T, Tian J, Qu W, Xie ZJ. Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay. J Biol Chem 2006; 281:19709-19719.
16. Tian J, Cai T, Yuan Z, Wang H, Liu L, Haas M, et al. Binding of Src to Na/K-ATPase forms a functional signaling complex. Mol Biol Cell 2006; 17:317-326.
17. Liu J, Tian J, Haas M, Shapiro JI, Askari A, Xie Z. Ouabain interaction with cardiac Na/K-ATPase initiates signal cascades independent of changes in intracellular Na and Ca2 concentrations. J BiolChem2000; 275:27838-27844.
18. Hamlyn JM, Harris DW, Ludens JH. Digitalis-like activity in human plasma. Puri?cation, af?nity, and mechanism. J Biol Chem 1989; 264:7395-7404.
19. Hamlyn JM. Discovery of endogenous ouabain: a new mammalian hormone. In: Bamberg E, Schoner W, editors. The sodium pump: structure, mechanism, hormonal control, role in disease. Proceedings of the VIIth International Conference on the Sodium Pump; 5-11 September 1993; Todtmoos, Germany; 1994.
20. Ludens JH, Clark MA, DuCharme DW, Harris DW, Lutzke BS, Mandel F, et al. Puri?cation of an endogenous digitalislike factor from human plasma for structural analysis. Hypertension 1991; 17 (6 Pt 2):923-929.
21. Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, Ludens JH. Mass spectral characterization of an endogenous digitalislike factor from human plasma. Hypertension 1991; 17 (6 Pt 2): 930-935.
22. Strobach H, Wirth KE, Rojsathaporn K. Absorption, metabolism and elimination of strophanthus glycosides in man. Naunyn Schmiedebergs Arch Pharmacol 1968; 334:496-500.
23. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, DuCharme DW. Development of an immunoassay for endogenous digitalislike factor. Hypertension 1991; 17 (6 Pt 2):936-943.
24. Seldin R, Margolies MN, Smith TW. Renal and gastrointestinal excretion of ouabain in dog and man. J Pharmacol Exp Ther 1974; 188:615-623.
25. Schneider R, Wray V, Nimtz M, Lehmann WD, Kirch U, Antolovic R, Schoner W. Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J Biol Chem 1998; 273:784-792.
26. Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert GT Jr, et al. On the structure of endogenous ouabain. Proc Natl Acad Sci USA 1999; 96:6654-6659.
27. Ludens JH, Clark MA, Robinson FG, DuCharme DW. Rat adrenal cortex is a source of a circulating ouabainlike compound. Hypertension 1992; 19 (6 Pt 2):721-724.
28. Manunta P, Rogowski AC, Hamilton BP, Hamlyn JM. Ouabain-induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. J Hypertens 1994; 12:549-560.
29. Rossi G, Manunta P, Hamlyn JM, Pavan E, De Toni R, emplicini A, Pessina AC. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma enin, aldosterone and blood pressure levels. J Hypertens 1995; 13:1181-1191.
30. Gottlieb SS, Ziskind AA, Lauria SS, Rodriguez S, Manunta P, Cines M, et al. Endogenous ouabain is produced in the adrenal gland in patients with congestive heart failure [abstract # I-255]. Circulation 1993; 88 (pt 2):1367.
31. Boulanger B, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, Gann DS. Ouabain is secreted by the adrenal gland in awake dogs. Am J Physiol 1993; 264 (3 Pt 1):E413-E419.
32. Manunta P, Evans G, Hamilton BP, Gann D, Resau J, Hamlyn JM. A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor [abstract # P36]. J Hypertens 1992; 10:S27.
33. Masugi F, Ogihara T, Hasegawa T, Sakaguchi K, Kumahara Y. Normalization of high plasma level of ouabain-like mmunoreactivity in primary aldosteronism after removal of adenoma. J Hum Hypertens 1988; 2:17-20.
34. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 1994; 135:794-797.
35. Laredo J, Shah J, Hamilton BP, Hamlyn JM. Alpha-1 adrenergic receptors stimulate secretion of endogenous ouabain from human and bovine adrenocortical cells. In: Taniguchi K, Kaya S, editors. Na/K-ATPase-related ATPases. Ninth International Conference on Na,K-ATPase and Related Pumps; 18-23 August 1999; Sapporo, Japan; 2000.
36. Sophocleous A, Elmatzoglou I, Souvatzoglou A. Circulating endogenous digitalis-like factor(s) (EDLF) in man is derived from the adrenals and its secretion is ACTH-dependent. J Endocrinol Invest 2003; 26:668-674.
37. Doris PA, Jenkins LA, Stocco DM. Is ouabain an authentic endogenous mammalian substance derived from the adrenal? Hypertension 1994; 23:632-638.
38. Lewis LK, Candele TG, Lewis Jg, Richerds AM, Pidgeon GB, Kaaja RJ, Nicholls MG. Ouabain is not detectable in human plasma. Hypertension 1994; 24:549-555.
39. Gomez-Sanchez EP, Foecking MF, Sellers D, Blankenship MS, Gomez- Sanchez CE. Is the circulating ouabain-like compound ouabain? Am J Hypertens 1994; 7:647-650.
40. el-Masri MA, Clark BJ, Qazzaz HM, Valdes R Jr. Human adrenal cells in culture produce both ouabain-like and dihydroouabain-like factors. Clin Chem 2002; 48:1720-1730.
41. Tymiak AA, Norman JA, Bolgar M, Di Donato GC, Lee H, ParkerWL, et al. Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci USA 1993; 90:8189-8193.
42. Komiyama Y, Nishimura N, Munakata M, Mori T, Okuda K, Nishino N, et al. Identi?cation of endogenous ouabain in culture supernatant of PC12 cells. J Hypertens 2001; 19:229-236.
43. Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, Ferrari P.Characteristics of a ouabain-like factor from Milan hypertensive rats. J Cardiovasc Pharmacol 1993; 22 (Suppl 2):S75-78.
44. Tamura M, Harris TM, Phillips D, Blair IA, Wang YF, Hellerqvist CG, et al. Identi?cation of two cardiac glycosides as Na()-pump inhibitors in rat urine and diet. J Biol Chem 1994; 269:11972-11979.
45. Vakkuri O, Arnason SS, Pouta A, Vuolteenaho O, Leppaluoto J. Radioimmunoassay of plasma ouabain in healthy and pregnant individuals. J Endocrinol 2000; 165:669-677.
46. Di Bartolo V, Balzan S, Pieraccini L, Ghione S, Pegoraro S, Biver P, et al. Evidence for an endogenous ouabain-like immunoreactive factor in human newborn plasma coeluted with ouabain on HPLC. Life Sci 1995; 57:1417-1425.
47. Komiyama Y, Nishimura N, Dong XH, Hirose S, Kosaka C, Masaki H, et al. Liquid chromatography mass spectrometric analysis of ouabain-like factor in biological ?uid. Hypertens Res 2000; 23 (Suppl):S21-S27.
48. Hamlyn JM, Laredo J, Shah JR, Lu ZR, Hamilton BP. 11-hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann NY Acad Sci 2003; 986:685-693. Hong BC, Kim S, Kim T-S, Corey EJ. Synthesis and properties of several isomers of the cardioactive steroid ouabain. Tetrahedron Lett 2006; 47:2711-2715.
49. Hamlyn JM, Lu ZR, Manunta P, Ludens JH, Kimura K, Shah JR, et al. Observations on the nature, biosynthesis, secretion and signi?cance of endogenous ouabain. Clin Exp Hypertens 1998; 20:523-533.
50. Murrell JR, Randall JD, Rosoff J, Zhao JL, Jensen RV, Gullans SR, Haupert GT Jr. Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 2005; 112:1301-1308.
51. Gruber KA, Rudel LL, Bullock BC. Increased circulating levels of an endogenous digoxin-like factor in hypertensive monkeys. Hypertension 1982; 4:348-354.
52. Worgall S, Hanze J,Wagner R, Peiser C, Lang RE, Sulyok E, RascherW. Characterization of ouabain-like immunoreactivity in human urine. J Hypertens 1996; 14:623-628.
53. Shilo L, Werber MM, Dolev S, Shapiro M, Shenkman L. Digoxin-like immunoreactivity: occurrence in three molecular forms and partial characterization. J Clin Endocrinol Metab 1987; 64:1257-1260.
54. Wauquier I, Pernollet MG, Grichois ML, Lacour B, Meyer P, Devynck MA. Endogenous digitalis-like circulating substances in spontaneously hypertensive rats. Hypertension 1988; 12:108-116.
55. Naruse K, Naruse M, Tanabe A, Yoshimoto T, Watanabe Y, Kurimoto F, et al. Does plasma immunoreactive ouabain originate from the adrenal gland? Hypertension 1994; 23 (Suppl 1):I102-I105.
56. Stokes GS, Norris LA, Marwood JF, Johnston H, Caterson RJ. Effect of dialysis on circulating Na,K ATPase inhibitor in uremic patients. Nephron 1990; 54:127-133.
57. Butt AN, Semra YK, Lane SJ, Lee T, Swaminathan R. Endogenous ouabain secretion in man is not regulated by ACTH. J Steroid Biochem Mol Biol 1998; 66:151-157.
58. Harwood S, Mullen AM, McMahon AC, Dawnay A. Plasma OLC is elevated in mild experimental uremia but is not associated with hypertension. Am J Hypertens 2001; 14:1112-1115.
59. Berendes E, Cullen P, Van Aken H, ZidekW, Erren M, Hubschen M, et al. Endogenous glycosides in critically ill patients. Crit Care Med 2003; 31:1331-1337.
60. Borsody M, Semenov I, Carroll K, Kessler A, Dobow J, Olson E, et al. The relation of brain ouabain-like compounds and idiopathic intracranial hypertension. Headache 2006; 46:1255-1260.
61. Balzan S, Nicolini G, Iervasi A, Di Cecco P, Fommei E. Endogenous ouabain and acute salt loading in low-renin hypertension. Am J Hypertens 2005; 18:906-909.
62. Anderson DE, Federova OV, Morrell CH, Longo DL, Kashkin VA, Metzler JD, et al. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Am J Physiol Regul Integr Comp Physiol 2008; 294:R1248-R1254.
63. Wang H, Leenen F. Brain sodium channels mediate increases in brain ouabain and blood pressure in Dahl S rats. Hypertension 2002; 40:96-100.
64. D'Urso G, Frascarelli S, Balzan S, Zucchi R, Montali U. Production of ouabain-like factor in normal and ischemic rat heart. J Cardiovasc Pharmacol 2004; 43:657-662.
65. Takahashi H, Matsusawa M, Okabayashi H, Suga K, Ikegaki I, Nishimura M, Yoshimura M. Endogenous digitalis-like substance in an adult population in Japan. Am J Hypertens 1988; 1(3Pt3):168S-172S.
66. Delva P, Devynck MA, DeganM, Pernollet MG, CarraroliM, Capra C, et al. Plasma levels of an endogenous Na-K pump inhibitor in relation to haemodynamic data in cardiopathic patients. Clin Sci (Lond) 1991; 81:23-29.
67. Chan JC, Butt A, Ho CS, Cockram C, Swaminathan R. Relation between blood pressure and serum concentration of ouabain-like substance in noninsulin-dependent diabetes mellitus. Lancet 1998; 351:266.
68. Vinge E, Erfurth EM, Odar-Cederlof I. Immunoreactive endogenous digoxin-like substances: plasma levels are dependent on the hypothalamic- pituitary-adrenal axis for release and on kidney function for elimination. J Cardiovasc Pharmacol 1993; 22 (Suppl 2):S112-S113.
69. Nakagawa M, Shimamoto K, Matsuda K, Saitoh S, Nakagawa H, Ura N, Iimura O. The transient increase of urinary digitalis-like substance excreted during excess sodium intake in reduced renal mass rats. Am J Hypertens 1990; 3:873-875.
70. Takahashi H, Matsusawa M, Suga K, Ikegaki I, NishimuraM, Yoshimura M, et al. Hypothalamic digitalis-like substance is released with sodium-loading in rats. Am J Hypertens 1988; 1:146-151.
71. Qazzaz HM, El-MasriMA, Valdes R Jr. Secretion of a lactone-hydrogenated ouabain-like effector of sodium, potassium-adenosine triphosphatase activity by adrenal cells. Endocrinology 2000; 141:3200-3209.
72. Shimabukuro N, Ebara H, Maruyama K, Tomizawa S, Kuroume T. Demonstration of the presence of digoxin-like immunoreactive substance (DLIS) in the serum and urine in children with nephrotic syndrome. Clin Nephrol 1988; 29:244-247.
73. Graves SW,Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnant women. J Clin Endocrinol Metab 1984; 59:1070-1074.
74. Goldstein I, Levy T, Galili D, Ovadia H, Yirmiya R, Rosen H, Lichtstein D. Involvement of Na, K-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry 2006; 60:491-499.
75. Semra YK, Butt AN, Swaminathan R. Effect of salt intake on excretion of endogenous ouabain-like substance, measured by RIA. Clin Chem 1996; 42:1949-1954.
76. Yuan W, Wang H, Lu Z, Yuan Y, Ren H. Relationship between serum or tissue ouabain and blood pressure in 1k1c hypertensive rats. Chin Med J (Engl) 2000; 113:595-598.
77. Goto A, Yamada K, Nagoshi H, Terano Y, Omata M. Stress-induced elevation of ouabainlike compound in rat plasma and adrenal.Hypertension 1995; 26 (6 Pt 2):1173-1176.
78. Wasada T, Kuroki H, Naruse M, Arii H, Maruyama A, Katsumori K, et al. Insulin resistance is associated with high plasma ouabain-like immunoreactivity concentration in NIDDM. Diabetologia 1995; 38:792-797.
79. Doris PA. Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol 1994; 266 (1 Pt 2):H360-H364.
80. Hinson JP, Dawnay AB, Raven PW. Why we should give a quali?ed welcome to ouabain: a whole new family of adrenal steroid hormones? J Endocrinol 1995; 146:369-372.
81. Nicholls MG, Richards AM, Lewis LK, Yandle TG. Ouabain: a new steroid hormone? Lancet 1995; 346:1381-1382.
82. Kelly RA, Smith TW. Is ouabain the endogenous digitalis? Circulation 1992; 2:694-697.
83. Hamlyn JM, Manunta P. Ouabain, digitalis-like factors and hypertension. J Hypertens 1992; 10 (Suppl 7):S99-S111.
84. Bagrov AY, Shapiro JI. Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 2008; 4:378-392.
85. Iwamoto T, Kita S. Hypertension, Na/Ca2 exchanger, and Na,K-ATPase. Kidney Int 2006; 69:2148-2154.
86. Adrogue'HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 2007; 356:1966-1978.
87. Goto A, Yamada K. Putative roles of ouabain-like compound in hypertension: revisited. Hypertens Res 2000; 23 (Suppl):S7-S13.
88. Takahashi H. Endogenous digitalis-like factor: an update. Hypertens Res 2000; 23 (Suppl):S1-S5.
89. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007; 293:C509-C536.
90. Wasserstrom JA, Aistrup GL. Digitalis: new actions for an old drug. Am J Physiol Heart Circ Physiol 2005; 289:H1781-H1793.
91. Van Huysse JW. Endogenous brain Na pumps, brain ouabain-like substance and the alpha2 isoform in salt-dependent hypertension. Pathophysiology 2007; 14:213-220.
92. Doris PA. Regulation of Na,K-ATPase by endogenous ouabain-like materials. Proc Soc Exp Biol Med 1994; 205:202-212.
93. Goto A, Yamada K, Yagi N, Yoshioka M, Sugimoto T. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992; 44:377-399.
94. Kitano S, Morimoto S, Nishibe A, Fukuo K, Hirotani A, Nakahashi T, et al. Exogenous ouabain is accumulated in the adrenals and mimics the kinetics of endogenous digitalis-like factor in rats. Hypertens Res 1998; 24:47-56.
95. Ferrandi M, Minotti E, Florio M, Bianchi G, Ferrari P. Age-dependency and dietary in?uence on the hypothalamic ouabain-like factor in Milan hypertensive rats. J Hypertens 1995; 13 (12 Pt 2):1571-1574.
96. Zhang H, Sridhar Reddy M, Phoenix S, Deslongchamps P. Total synthesis of ouabagenin and ouabain. Angew Chem Int Ed Engl 2008; 47:1272-1275.
97. Bauer N, Muller-Ehmsen J, Kramer U, Hambarchian N, Zobel C, Schwinger RH, et al. Ouabain-like compound changes rapidly on physical exercise in humans and dogs: effects of beta-blockade and angiotensin-converting enzyme inhibition. Hypertension 2005; 45:1024-1028.
98. Bernini G, Paci A, Sgro M, Moretti A, Salvetti A. Endogenous digitalis-like factor and ouabain immunoreactivity in adrenalectomized patients and normal subjects after acute and prolonged salt loading. Am J Hypertens 1998; 11 (1 Pt 1):1-7.
99. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P.Ouabain-like factor quanti?cation in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997; 30:886-896.
100. Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, et al. Left ventricular mass, stroke volume and ouabain-like factor in essential hypertension. Hypertension 1999; 34:450-456.
101. Lichtstein D, Steimitz M, Gati I, Samuelov S, Deutsch J, Orly J. Bufodienolides as endogenous Na K-ATPase inhibitors: iosynthesis in bovine and rat adrenals. Clin Exp Hypertens 1998; 20:573-579.
102. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, Bagrov AY. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17:1179-1187.
103. Fredline V, Taylor PJ, Dodds HM, Johnson AG. A reference method for the analysis of aldosterone in blood by high performance liquid chromatography- atmospheric pressure chemical ionization-tandem mass spectrometry. Anal Biochem 1997; 252:308-313.
104. Manunta P, Hamilton BP, Hamlyn JM. Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 2006; 290:R553-R559.
105. Wang JG, Staessen JA, Messaggio E, Nawrot T, Fagard R, Hamlyn JM, et al. Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens 2003; 21:1475-1481.
106. Pierdomenico SD, Bucci A, Manunta P, Rivera R, Ferrandi M, Hamlyn JM, et al. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am J Hypertens 2001; 14:44-50.
107. Manunta P, Iacoviello M, Forleo C, Messaggio E, Hamlyn JM, Lucarelli K, et al. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J Hypertens 2005; 23:1677-1681.
108. Pitzalis MV, Hamlyn JM, Messaggio E, Iacoviello M, Forleo C, Romito R, et al. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur J Heart Fail 2006; 8:179-186.
109. Stella P, Manunta P, Mallamaci F, Melandri M, Spotti D, Tripepi G, et al. Endogenous ouabain and cardiomyopathy in dialysis patients. J Intern Med 2008; 263:274-280.
110. Manunta P, Maillard M, Tantardini C, Simonini M, Lanzani C, Citterio L, et al. Relationships among endogenous ouabain, alpha-adducin polymorphisms and renal sodium handling in primary hypertension. J Hypertens 2008; 26:914-920.
111. Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, et al., Salt Sensitivity Study group of the Italian Society of Hypertension. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 2001; 38:198-203.
112. Manunta P, Ballabeni C, Ferrandi M, Barassi P, Messaggio E, Lanzani C, et al. Modulation of endogenous ouabain response to salt challange by alpha adducin polymorphism in rats and humans [abstract # P3]. Hypertension 2002; 40:395.